Pre-eclampsia as a manifestation of antiphospholipid syndrome: Assessing the current status

Karen Gibbins, D. Ware Branch

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The presence of antiphospholipid antibodies is considered a risk factor for pre-eclampsia. Two meta-analyses and a number of case-control and cohort studies have found associations between pre-eclampsia and lupus anticoagulant, anticardiolipin, and/or anti-β2 glycoprotein I. However, existing literature is inconsistent, with varying severity of pre-eclampsia phenotype examined, differing aPL titer cutoffs used to define positive status, and an overwhelming lack of repeat confirmatory aPL testing. This calls into question the link between aPLs and pre-eclampsia, or at least makes it less well defined. There is evidence for a mechanistic pathway between aPLs and adverse pregnancy outcomes (APOs) including pre-eclampsia via the complement pathway. Complement appears to be overactive in pregnancies affected by APOs. A mouse model has show that the fetal wastage caused by treatment with human aPLs can be salvaged by either creating genetic knockouts along the complement, TNF-alpha, and tissue factor pathways or be treating mice with monoclonal antibodies blocking key complement factors. Thus, this is worth further investigation to clarify the likely association of aPLs and pre-eclampsia in humans, as well is to further evaluate the interaction with complement in human pregnancies.

Original languageEnglish (US)
Pages (from-to)1229-1231
Number of pages3
JournalLupus
Volume23
Issue number12
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Antiphospholipid Syndrome
Pre-Eclampsia
Pregnancy Outcome
Lupus Coagulation Inhibitor
Pregnancy
Antiphospholipid Antibodies
Thromboplastin
Meta-Analysis
Case-Control Studies
Glycoproteins
Cohort Studies
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Phenotype

Keywords

  • Antiphospholipid syndrome
  • complement
  • pre-eclampsia

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Pre-eclampsia as a manifestation of antiphospholipid syndrome : Assessing the current status. / Gibbins, Karen; Ware Branch, D.

In: Lupus, Vol. 23, No. 12, 01.01.2014, p. 1229-1231.

Research output: Contribution to journalArticle

@article{5efac63c1c4941aea05251e21e77b4b2,
title = "Pre-eclampsia as a manifestation of antiphospholipid syndrome: Assessing the current status",
abstract = "The presence of antiphospholipid antibodies is considered a risk factor for pre-eclampsia. Two meta-analyses and a number of case-control and cohort studies have found associations between pre-eclampsia and lupus anticoagulant, anticardiolipin, and/or anti-β2 glycoprotein I. However, existing literature is inconsistent, with varying severity of pre-eclampsia phenotype examined, differing aPL titer cutoffs used to define positive status, and an overwhelming lack of repeat confirmatory aPL testing. This calls into question the link between aPLs and pre-eclampsia, or at least makes it less well defined. There is evidence for a mechanistic pathway between aPLs and adverse pregnancy outcomes (APOs) including pre-eclampsia via the complement pathway. Complement appears to be overactive in pregnancies affected by APOs. A mouse model has show that the fetal wastage caused by treatment with human aPLs can be salvaged by either creating genetic knockouts along the complement, TNF-alpha, and tissue factor pathways or be treating mice with monoclonal antibodies blocking key complement factors. Thus, this is worth further investigation to clarify the likely association of aPLs and pre-eclampsia in humans, as well is to further evaluate the interaction with complement in human pregnancies.",
keywords = "Antiphospholipid syndrome, complement, pre-eclampsia",
author = "Karen Gibbins and {Ware Branch}, D.",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/0961203314531347",
language = "English (US)",
volume = "23",
pages = "1229--1231",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Pre-eclampsia as a manifestation of antiphospholipid syndrome

T2 - Assessing the current status

AU - Gibbins, Karen

AU - Ware Branch, D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The presence of antiphospholipid antibodies is considered a risk factor for pre-eclampsia. Two meta-analyses and a number of case-control and cohort studies have found associations between pre-eclampsia and lupus anticoagulant, anticardiolipin, and/or anti-β2 glycoprotein I. However, existing literature is inconsistent, with varying severity of pre-eclampsia phenotype examined, differing aPL titer cutoffs used to define positive status, and an overwhelming lack of repeat confirmatory aPL testing. This calls into question the link between aPLs and pre-eclampsia, or at least makes it less well defined. There is evidence for a mechanistic pathway between aPLs and adverse pregnancy outcomes (APOs) including pre-eclampsia via the complement pathway. Complement appears to be overactive in pregnancies affected by APOs. A mouse model has show that the fetal wastage caused by treatment with human aPLs can be salvaged by either creating genetic knockouts along the complement, TNF-alpha, and tissue factor pathways or be treating mice with monoclonal antibodies blocking key complement factors. Thus, this is worth further investigation to clarify the likely association of aPLs and pre-eclampsia in humans, as well is to further evaluate the interaction with complement in human pregnancies.

AB - The presence of antiphospholipid antibodies is considered a risk factor for pre-eclampsia. Two meta-analyses and a number of case-control and cohort studies have found associations between pre-eclampsia and lupus anticoagulant, anticardiolipin, and/or anti-β2 glycoprotein I. However, existing literature is inconsistent, with varying severity of pre-eclampsia phenotype examined, differing aPL titer cutoffs used to define positive status, and an overwhelming lack of repeat confirmatory aPL testing. This calls into question the link between aPLs and pre-eclampsia, or at least makes it less well defined. There is evidence for a mechanistic pathway between aPLs and adverse pregnancy outcomes (APOs) including pre-eclampsia via the complement pathway. Complement appears to be overactive in pregnancies affected by APOs. A mouse model has show that the fetal wastage caused by treatment with human aPLs can be salvaged by either creating genetic knockouts along the complement, TNF-alpha, and tissue factor pathways or be treating mice with monoclonal antibodies blocking key complement factors. Thus, this is worth further investigation to clarify the likely association of aPLs and pre-eclampsia in humans, as well is to further evaluate the interaction with complement in human pregnancies.

KW - Antiphospholipid syndrome

KW - complement

KW - pre-eclampsia

UR - http://www.scopus.com/inward/record.url?scp=84908674556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908674556&partnerID=8YFLogxK

U2 - 10.1177/0961203314531347

DO - 10.1177/0961203314531347

M3 - Article

C2 - 25228712

AN - SCOPUS:84908674556

VL - 23

SP - 1229

EP - 1231

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 12

ER -